Nod scid il2rγ null mice
NOD/SCID/IL2Rγ-null mice are an immunodeficient mouse strain that lacks mature T cells, B cells, and NK cells. This strain is commonly used in xenograft and cell transplantation studies.
Lab products found in correlation
32 protocols using nod scid il2rγ null mice
Lentiviral Transduction of PDX Models
Establishing Glioblastoma Xenograft Model
Establishing Merkel Cell Carcinoma Xenograft Model
Orthotopic Breast Tumor Metastasis Assay
Pseudoislet Transplantation in NOD Mice
In Vivo Tumor Growth Modulation
In vivo CRISPR knockdown of SOX2 enhancer
Evaluating Tumour Growth and Metastasis in Mice
For subcutaneous tumour growth assays, cells were dissociated into single-cell suspensions using non-enzymatic cell dissociation solution (Sigma Biochemicals) and numbers of live cells were counted following trypan blue staining (Thermo Fisher Scientific). Cell suspension in 50 μl of 4.5 mg ml−1 Matrigel (BD Biosciences) in Hank's balanced salt solution was subcutaneously injected into flanks of NIH-III nude mice (Charles River). Tumours were measured three dimensionally two to three times a week for 17–20 days. For tail vein assays, 150 μl of cell suspension (5 × 104) was injected into the lateral veins of nude mice. Mice were monitored for laboured breathing and the numbers of pulmonary tumour nodules were evaluated 6 weeks after injections. For orthotopic injections, 15 μl of cell suspension (1 × 105) was injected into femoral bone marrow space of anaesthetized NOD-scid IL2Rγnull mice (The Jackson Laboratories)22 (link). When the tumours reached ∼1 cm in thigh diameter, the mice were killed. The weight of the primary tumours and numbers of tumour nodules in the lungs and liver (>0.5 mm) were measured.
In vivo Efficacy of Compound 14 Against Malaria
measured against P. falciparumPf3D70087/N9 growing in the peripheral
blood of NOD-scidIL2Rγnull mice (Jackson Laboratory,
USA) (23–36 g) engrafted with human erythrocytes as described.47 (link) Human biological samples were sourced and used
in accordance with the terms defined in the informed consent of the
IRB/EC-approved protocol. The parasites (20 × 106)
were inoculated by intravenous injection, and antimalarial efficacy
was assessed using a standard “4-day test”. Blood parasitemia
was measured by FACS analysis. Compound
in vehicle (1% methylcellulose) by oral gavage QD for four consecutive
days starting on the third day after infection. The actual administered
doses were determined by the measurement of the formulation concentrations.
The compound concentrations in either the formulations or the blood
from the infected mice were measured by LC–MS–MS (described
above). The efficacy markers (ED90, AUCED90)
were determined on the seventh day after infection, one day after
the last dose.
Mouse Xenograft Model of Leukemia
Experiments were performed according to Animal Care and Use Committee’s guidelines.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!